Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 646-654

  Frankfort, Suzanne V ^a   Appels, B A ^a   De Boer, A ^b   Tulner, L R ^a   Van Campen, J P C M ^a   Koks, C H W ^a   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; CAMCOG; Clinical care; Effectiveness; IDDD; Neuropsychological assessment; Rivastigmine; RMBPC

Indexed keywords

RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CALCULATION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE EXACERBATION; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; OUTPATIENT CARE; PRIORITY JOURNAL; STANDARDIZATION; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMBULATORY CARE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; PHENYLCARBAMATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33744539828     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00970.x     Document Type: Article

References (38)

1. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
2. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial. BMJ 1999; 318: 633-8.
3. Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J et al. Differential efficacy of treatment with acetylcholinesterase inhibitors with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005; 19: 189-95.
4. Mossello E, Tonon E, Caleri V et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study. Arch Gerontol Geriatr 2004; 9: S297-S307.
5. Small GW, Kaufer D, Mendiondo MS et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-7.
6. Johanssen P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 2004; 18: 757-68.
7. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 100-8.
8. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9: 101-24.
9. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998; 11: 211-6.
10. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004; 26: 980-90.
11. Aupperle PM, Koumaras B, Chen M et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioural disturbances in nursing home residents with moderate to severe Alzheimer's disease: Results of a 52-week open-label study. Curr Med Res Opin 2004; 20: 1605-12.
12. Hatoum HT, Lin SJ, Arcona S et al. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behaviour of nursing home residents with Alzheimer's disease. J Am Med Dir Assoc 2005; 6: 238-45.
13. Cummings JL, Koumaras B, Chen M et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137-48.
14. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
15. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state' a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
16. Roth M, Tym E, Mountjoy CQ et al. CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
17. Schmand B, Walstra G, Lindeboom J, Teunisse S, Jonker C. Early detection of Alzheimer's disease using the Cambridge cognitive examination (CAMCOG). Psychol Med 2000; 30: 619-27.
18. Teunisse S, Derix MM. Measuring functional disability in community-dwelling dementia patients: Development of a questionnaire (in Dutch). Tijdschr Gerontol Geriatr 1991; 22: 53-9.
19. Teri L, Truax P, Logsdon R, Uomoto J, Zarit S, Vitaliano PP. Assessment of behavioral problems in dementia: The revised memory and behavior problems checklist. Psychol Aging 1992; 7: 622-31.
20. Verhage F. Intelligence and Age (in Dutch). Assen: Van Gorcum, 1964.
21. Public Health Board. Diagnostics in Dementia (in Dutch). Amstelveen: Public Health Board, 1998.
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1969.
23. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 677-85.
24. Frankfort SV, Appels BA, de Boer A et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry 2005; 20: 1167-71.
25. Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. J Am Geriatr Soc 1992; 40: 922-35.
26. Grossberg GT. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: Review of neuropsychiatric impairment in Alzheimer's disease. Curr Med Res Opin 2005; 10: 1631-9.
27. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease. Am J Geriatr Psychiatry 2004; 12: 358-69.
28. Lopez OL, Becker JT, Somsak D et al. Awareness of cognitive deficits and anosognosia in probable Alzheimer's disease. Eur Neurol 1994; 34: 277-82.
29. Harwood DG, Sultzer DL, Wheatly DV. Impaired insight in Alzheimer's disease: Association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13: 83-8.
30. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: A meta analysis. JAMA 2003; 289: 210-6.
31. Farlow M, Potkin S, Koumaras B et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26 week, Alzheimer disease trial. Arch Neurol 2003; 60: 843-8.
32. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 25: CD005593.
33. Grossberg G, Irwin P, Satlin A et al. Rivastigmine in Alzheimer's disease: Efficacy over two years. Am J Geriatr Psychiatry 2004; 12: 420-31.
34. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001; 20: 51-6.
35. Teunisse S, de Haan R, Walstra GJM et al. Behavioural problems in mild dementia: Clinical relevance and methodological evaluation of the Revised Memory and Behavioural Problems Checklist. In: Teunisse S. Clinimetrics in Dementia [Thesis] Amsterdam: University of Amsterdam 1997; 71-85.
36. Garre-Olmo J, López-Pousa S, Vilalta-Franch J et al. Neuropsychological profile of Alzheimer's disease in women: Moderate and moderately severe cognitive decline. Arch Womens Ment Health 2004; 7: 27-36.
37. Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. CAMCOG - a concise neuropsychological test to assist dementia diagnosis: Socio-demographic determinants in an elderly population sample. Br J Clin Psychol 1995; 34: 529-41.
38. Williams JG, Huppert FA, Matthews FE, Nickson J. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. Int J Geriatr Psychiatry 2003; 18: 631-44.